We previously found follistatin (FS) mRNA in gonadotropes [predominantly in cells with luteinizing hormone (LH) antigens] and folliculostellate cells (with SlOO antigens) in diestrous rats pituitaries. However, earlier in the cyde, when percentages of gonadotropes are lowest, percentages of cells expressing FS are 1.5-2-fold higher than in diestrus. This study was designed to detect FS mRNA and other pituitary antigens to identdy the additional cells with dual in situ hybridization and immunolabeling protocols. The mRNA was detected with biotinylated complementary oligonucleotide probes and avidin-biotin-peroxidase complexes. Significant labeling for FS mRNA was found in cells with the following antigens: growth hormone (GH) (7% of pituitary cells); prolactin (PE) (5%); Slooprotein (5%); follicle-stimulating hormone (FSHP) (4%); LHP (3%); and thyroid-stimulating hormone (TSHB) (3%). Optimal conditions for detection included: overnight plating of >50,000 cellstwell (24-well tray) in media containing 10% fetal bovine serum; hybridization at 37°C; and fmtion in 2% glutaraldehyde. Whereas FS is expressed predominantly by LH gonadotropes at midcycle, FS mRNA can be expressed by all types of antigenbearing cells earlier in the cycle. Its function in the pituitary may relate to its role in binding activin, which would result in inhibition of FSH release. However, since activin inhibits secretion of GH, PRL, and adrenocorticotropin (ACTH), FS may also control activin's effects on these cells. The FS-expressing cells may therefore be paraaine or a u t d n e regulators. (J Histochem Cyrochem 41:955-%U, 1993) 
In ttoduction
Follistatin (FS) is a single-chain polypeptide isolated from porcine ovarian follicular fluid in 1986 (1). It inhibited follicle-stimulating hormone (FSH) release from primary cultures of rat pituitary cells (2-5). In 1989, Gospodarowicz and Lau (6) tested conditioned media from monolayers of bovine folliculostellate cells and found FS activity in fractions derived from this media. This suggested that pituitary folliculostellate cells could synthesize and secrete FS as part of a local paracrine regulating system.
In 1990, Michel et al. (7) investigated the distribution of FS mRNA in rat gonadal and extragonadal tissues with a radiolabeled cDNA probe. FS mRNA was detected in a number of extragonadal tissues including brain and pituitary, suggesting that it serves as a ubiquitous regulatory polypeptide. Nakamura et al. (8) reported that ovarian FS binds activin, a polypeptide that stimulates FSH release (4, 9) . In 1991, Kogawa et al. (10) identified an activin-binding protein in bovine pituitary. On further analysis it was identical to FS, confirming earlier studies (6). This finding also suggested a paracrine mechanism whereby FS may regulate FSH release. Recently, Kaiser et al. (11) measured FS mRNA in pituitary by both ribonuclease (RNAse) protection assays and the polymerase chain reaction (PCR). Collaborative studies in our laboratory applied dual labels for FS mRNA and the P-subunits of luteinizing hormone (LHP), follicle-stimulating hormone (FSHP), or S-100 protein to cells from female rats taken on the second day of diestrus (diestrous-11). FS mRNA was localized in cells that stored LHP and, to a lesser extent, in cells that stored FSHP and SI00 protein. Since SI00 protein is believed to be a marker for folliculostellate cells, this last finding confirmed the work of Gospodarowicz and Lau (6).
However, after these initial studies were completed, it became clear that expression of FS mRNA was higher earlier in the estrous cycle. On the morning of metestrus there were 13.5% cells with label for FS mRNA compared with 6-7% later in the cycle. Since in metestrus there is low expression ofgonadotropin antigens (12,13), we hypothesized that the additional cells might come either from the folliculostellate cells, from other cell types, andlor from gonadotropes that store too little LH or FSH for detection. Therefore, studies were initiated to identify sites of label for FS mRNA with in situ hybridization using a biotinylated complementary oligonucleotide probe (12-15) and sites of antigens by immunolabeling for each of the pituitary hormones (14J6). This report focuses on results that show optimized times and conditions for detection of FS mRNA in different pituitary cell types. It identifies the cell types that express the mRNA early in the estrous cycle.
Materials and Methods
Optimization of Culture Conditions. In pilot studies, three to five rats from different stages of the estrous cycle were tested (0900 hr) to determine when the highest percentages of cells with FS mRNA were produced. The stages were determined by vaginal smears and rats were used only if they had completed two normal estrous cycles (12J3.17).
Cells were dissociated and plated at 25,000-60,000 cellslwell(24-well trays) in a 50-pl drop. The pH of the media was 7.6-7.8 to facilitate rapid plating to the glass (usually within 15 min). Then 400 p1 of Dulbecco's modified Eagle's medium (DME) URH Biosciences; Lenexa, KS) was added and the cells were allowed to plate further for 1, 3, 15, or 24 hr. Insulin (UBI; Lake Placid, NY), sodium selenite (Sigma; St Louis, MO), transferrin (Sigma), and fibronectin (Chemicon; Temecula, CA) were added to the DME as described previously (12) (13) (14) . Parallel groups of cells were plated as described above; however, they were grown for 15-24 hr in DME containing 10% fetal bovine serum (FBS) (Hazelton; Lenexa, KS).
Just before fixation the cells were washed three times in DME to remove excess FBS. Then they were fixed in 2% glutaraldehyde for 30 min at room temperature [diluted in 0.1 M phosphate buffer (PB), pH 7.41 or 2 hr in 4% paraformaldehyde (diluted in PB) at 4'C. After fmtion the cells were washed four times in 0.1 M PB (pH 7.4) containing 4.5% sucrose and stored at 2-3°C for no more than 1 week. The buffers and washing solutions wete sterile and kept frozen until used for the fixative.
Optimization of In Situ Labeling Protocols. The sense and anti-sense oligonucleotide probes were 50-mer sequences described in our previous report (11). The pilot studies in 1990 employed synthetic sense and antisense oligonucleotide probes provided by Drs. Ursula Kaiser and Wm. Chin (11). In 1991, the complementary oligonucleotide probes were synthesized either by the University of Texas Medical Branch Molecular Biology laboratory or Genosys (Houston, TX). Quantitative data presented here were obtained with the Genosys oligonucleotide probe.
The probes were photobiotinylated in units of 10 pg (IO pI) with equal amounts of the Vector Photoprobe biotin kit (Vector; Burlingame, CA). The latest protocol is described in a separate report (18) . Pre-hybridization and hybridization steps were done on fixed cells collected fresh that week. The protocol was identical to that previously described (12-15J8). Detection of biotin on the hybrids was done by the avidin-biotin-peroxidase complex (Vector) and nickel-intensified diaminobenzidine (12-14).
When signal was obtained with the complementary biotinylated probe, optimal conditions for labeling and specificity of the reactions were tested. The first test employed different concentrations of the biotinylated oligonucleotide probes to determine the point at which hybridization sites were saturated. During this test cells were hybridized for either 2 hr or overnight with different concentrations ranging from 0.1-500 nglml. In another test the temperature of hybridization varied from 34-43'C.
To test the labeling specificity, the biotinylated sense sequence of FS mRNA was substituted for the biotinylated anti-sense sequence. Concentrations were 250-500 nglml. Hybridization buffer alone was also used to detect nonspecific reactions from the avidin reagents.
Optimization of Immunolabeling Protocols. Pituitary hormones were detected with antisera in protocols modified from those described in Childs et al. (14J6). Modifications included adding 5 % non-fat dry milk (Carnation) to the diluent buffers for both the blocking solution (5% normal goat serum) and the primary antisera. Thus, the diluent buffer contained 0.05 M PB + 0.25% human serum albumin + 5% normal goat serum + 5% non-fat dry milk. Optimal working dilutions were: anti-bovine LHP (a kind gift from Dr. John Pierce; Cambria, CA), 1:110,000; anti-human FSHP, 1:10,000; anti-rat thyroid-stimulating hormonep (TSHP), 1:10,500; antirat growth hormone (GH), 1:20,000 anti-rat prolactin (PIU), 1:15,000 (all obtained from the NIDDK Hormone Distribution Program; Bethesda, MD); anti-ACTH [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , 1:25,000 (produced in our laboratory). These antisera were used in both single-and dual-labeling protocols. Counts of labeled cells were compared after both protocols to determine if the in situ protocol had affected the localization of the antigens.
Specificity tests for these antisera were done by absorbing each with its respective antigen for 2 hr. Then the absorbed and unabsorbed anusera were used to detect the antigens after in situ hybridization. Tests showed that 0.5-5 pglml of each antigen neutralized labeling by its antibody. A new immunocytochemical test for SI00 protein, a marker for folliculostellate cells, was also developed with antisera from Dakopatts (Glostrup, Denmark). Optimal dilutions tested in dual-and single-labeling protocols were 1:15,000 and 1:30,000, respectively. When 10-100 nglmlSl00 protein (Calbiochem; San Diego, Ca.) was added to the diluted antisera for 2 hr, the labeling was neutralized Analysis of Labeled Fields. In the pilot studies, cells from three to five rats from different stages of the cycle were analyzed after single labeling for FS mRNA to learn which stage produced the highest percentages. Cells from metestrous rats exhibited the highest expression and were therefore used to optimize the dual labeling for the pituitary antigens. Very low percentages (less than 6% of pituitary cells) were seen during proestrus. Six different cell metestrous populations were studied in separate experiments.
The cells were plated on glass coverslips in a 24-well my. The trays were subdivided as follows: At least three coverslips were used for single-labeling protocols on which cells with FS mRNA were counted. The remaining coverslips were dual labeled for FS mRNA and each of the pituitary hormones or SI00 protein (three each).
Labeled and unlabeled cells were analyzed (at least 50lfield in three to 10 fields) and categorized. A Lotus 123 program was developed in which the percentages of each category (% with mRNA, % with antigen, and % with both mRNA and antigen) were calculated automatically. The percentage of total pituitary cells that contained the hormone and mRNA were also calculated.
The percentages of hbrmone-or mRNA-bearing cell populations from the dual labeling were also compared with those from single labeling to ensure that the dual-labeling protocol had not interfered with detection of either the mRNA or the antigen. The average of the percentages 0fmRNAcontaining cells for each cell population was derived from values for all 24 coverslips (three single labeled and 21 dual labeled for the different antigens). The data reported here are the average of the six experiments. Significant differences between the cells labeled with sense and anti-sense oligonucleotide probes were determined by Student's t-test.
Results

Detection of FS mRNA in Individual Pituitary CeLls
FS mRNA was found in medium-to-large round or lobulated cells and very small cells with processes. It was frequently in large patches, in whorls, or in a linear pattern (several parallel lines). Figure 1 shows the distribution and pattern of labeling for FS mRNA in individual cells. After 2 4 hr in culture pituitary cells had several blunt processes, usually 2-5 pm in diameter. Extension of these processes could be seen in healthy living cells that were actively secreting. The insets show examples of labeling at a higher magnification.
As the cells formed one to three blunt processes during the first 2 4 hr in culture, they began to resemble a small cluster of grapes. Phase-contrast microscopy was therefore used to confirm that these cells are in fact single cells (by the presence of a single nucleus). In the figures, the focal plane was set to capture the label and the nucleus is not evident unless it is outlined by label for mRNA or antigens.
With biotinylated sense sequences, an occasional cell showed labeling similar to that in the field labeled with the anti-sense probe. However, counts of the percentages of labeled cells after exposure to sense sequence or hybridization buffer alone revealed labeling in only 0.345% of the population. Occasionally higher background labeling was evident. Tests showed that achieving low background levels required freshly deionized formamide in the hybridization buffer and the prehybridization steps. Figure 2 shows a field ex- posed to biotinylated sense oligonucleotide for FS mRNA in which background was negligible. Studies of cells in different stages of the cycle showed that the highest percentages of cells with FS mRNA were in cell populations from metestrous rats taken at 0900 hr. These populations had 13.5 f 1% cells with FS mRNA (average of six experiments sampling a total of 14,836 cells r SD). Pilot studies showed that the lowest percentages came from rats taken in the afternoon of diestrus or proestrus (5-6% labeled cells) (data not shown).
-
Cell Types That Express FS mRNA
Dual-labeling tested expression of FS mRNA by cells bearing pituitary antigens. Those bearing LH, FSH, and SI00 protein antigens were described previously in a group of five diestrous I1 rats (11).
In the present study of metestrous rats, a survey of the other cell types showed that FS mRNA could be expressed by subtypes of most of the pituitary cells. Figure 3 illustrates the distribution of FS mRNA among the different cell types. Because the concentration of each cell type in the pituitary population is different, the impact of cells with FS mRNA on the total population is best seen expressing their numbers as percentages of total pituitary cell population. Figure 3 shows that cells with FS mRNA and GH antigens are the most abundant (7% of pituitary cells). The next abundant group are cells with SI00 or PIU antigens (each representing 5% of pituitary cells).
Gonadotropes and thyrotropes with FS mRNA are only 3-4% of the pituitary cells. The percentages of corticotropes with FS mRNA are not different from those in the control populations in which the anti-sense mRNA probe was omitted. Figure 4 illustrates examples of dual labeling for FS mRNA in GH-containing cells. Label for FS mRNA is seen in small ( Figure  4a ) and medium-sized (Figure 4c ) GH cells. In Figure 4b a GH cell expressing FS mRNA (Cell a) lies next to a cell with only FS mRNA (Cell b).
Optimal Labeling Conditions for Follistatin mRNA
Tests of the in situ hybridization protocol demonstrated optimal labeling after hybridization overnight at 37°C. It was weaker ifthe hybridization time was reduced to 2 hr (at 37°C). Labeling disappeared ifthe temperature dropped below 36°C. After the optimal temperature was determined, saturation of labeling sites was detected by counting the percentages of labeled cells after exposure to 0.1-500 ng/ml of complementary oligonucleotide probes. In the diestrous rats (11), the highest percentages were seen with concentrations greater than 100 nglml. However, the labeling was light and diffuse in some cells. Therefore, to bring out the signal at all sites, labeling was routinely done with 250 nglml. Finally, a comparison of the two fixatives (paraformaldehyde and glutaraldehyde) showed that glutaraldehyde fixation resulted in superior morphology and labeling of higher intensity.
Tests of the different plating times showed that populations plated for 15-24 hr were more reliable for localization of FS &A. In populations plated for only 1 hr, the percentages of labeled cells were similar to those of the 1-day cultures; However, the cells did not adhere as well and we reasoned that signal from the most weakly labeled cells might be missed. Tests of the different stages of the cycle showed that the cells retained the memory of the physiological state. Percentages of labeled cells at each stage did not change during the 24-hr plating period.
Plating in defined media (without 10% FBS) overnight resulted in loss of the monolayer during in situ hybridization. The substrate laid down by the cells did not adhere well to the glass coverslip (even if poly-L-lysine was used during plating) and the entire monolayer floated in the wash solutions after hybridization. Freshly plated monolayers (within 3-4 hr of plating) remained attached to the coverslip. Although they could be used for labeling, the intensity was not as high. Monolayers plated at pH 7.6-7.8 on bare glass and grown in 10% FBS overnight remained well attached during the washes. Therefore, for the remainder of the study the monolayers were grown for 15-24 hr in DME containing 10% FBS.
Plating density also affected the labeling for FS mRNA. requiring densities of 50,000-60,000 cells/coverslip. Analysis of the dual-and single-labeled populations showed that the dual-labeling protocol had not interfered with localization of the mRNA or the antigens. There were no significant differences in the percentages of cells with FS mRNA or individual antigens between single-labeled fields and fields co-labeled for any one of the seven antigens tested.
Discussion
The purpose of this and the previous study (11) was to localize FS mRNA in monolayers of pituitary cells along with pituitary antigens to determine which cell types had the potential to express the mRNA. Dual labeling for the mRNA followed by immunolabeling for pituitary antigens detected expression in different cell types.
Optimization of Labeling Protocols
Immunolabeling did not interfere with the detection of FS &A, and tests of the dual-labeling protocol showed that percentages of antigen-bearing cells were similar to those from single-labeled fields (19) . This important validation step indicates that the extra time in culture and the in situ hybridization protocol had not interfered with the detection of antigens. The second label neither covered nor washed out the first label. These data agree with those from previous reports of cells bearing LHP mRNA and LH or FSH antigens (16) . Furthermore, the specificity tests showed that the antisera could be neutralized by their respective antigens, resulting in no second label after the in situ protocol was used for the first label. This not only confirmed previous specificity tests on the same antisera but also showed that the orange peroxidase reaction product depended on a complete sequence of reagents in the immunolabeling protocol.
Broad Expression of FS mRNA During Metestms
The earlier studies used a group of diestrous rats to correlate data with the assay results (11). However, populations from these rats have relatively low percentages of cells labeled for FS "A.
Furthermore, the dual-labeling studies were limited to identification of cells with gonadotropin or SlOO antigens, In that study, 70% of the cells labeled for FS mRNA were LH gonadotropes and 20% were FSH gonadotropes and we hypothesized that these cells were autocrine regulators of FSH secretion (1 1). The remaining cells labeled for FS mRNA were characterized by their content of SI00 antigen as folliculostellate cells. This population may function as paracrine regulators.
The present studies concentrated on metestrous rats because of the twofold higher percentages of cells with FS mRNA compared with the other stages. However, this stage is also characterized by relatively low concentrations of LH or FSH gonadotropes in the pituitary cell population (12,13). Therefore, it was of interest to learn if the additional FS-expressing cells were folliculostellate cells andlor one of the other cell types. Analysis of this group of rats showed that subtypes of most pituitary cells can express FS mRNA early in the cycle. The most abundant group are subtypes of GH cells.
It is important to note that adding total percentages of all types of cells expressing FS mRNA (Figure 3) results in higher percentages of pituitary cells than those determined from actual counts of FS cells (13.5% of over 14,000 counted cells). This may reflect the fact that many of the antigens are stored jointly in the pituitary, most notably LH, FSH, and/or ACTH, GH and PRL, ACTH and TSH, and TSH and GH and/or PRL (reviewed in 14). Thus, as hypothesized for the broad distribution of the triiodothyronine receptor (14) FS mRNA may be localized in a multihormonal or multipotential cell type. Triple-labeling protocols would be needed to confirm this hypothesis.
Finally, when any immunolabeling data are analyzed, it is important to recognize that detection of antigens at a particular site does not necessary reflect a storage site. The antigens may also be identified at binding sites in target cells, and such relationships exist in the anterior pituitary cell population.
Sign$cance of Pituitary FS
The significance of the expression of FS by the different pituitary cell types may relate to its role in the binding of activin (8). Activin itself may be secreted from the pituitary gonadotropes (20) and therefore may be a local stimulator of FSH synthesis, release, and growth of the FSH gonadotrope population (4,9,20-23). However, more recent studies show that activin also inhibits release of GH (24,25), PRL (26), and synthesis and secretion of ACTH from Afl20 tumor cells (27) . Therefore, the production of FS early in the cycle may represent a paracrine or autocrine form of regulation. For example, if GH or PRL cells secrete FS, this may bind activin and prevent their inhibition. At the same time, removal of activin would keep FSH secretion in check during metestrus. It is interesting to note that the expression of FS mRNA is highest when FSH synthesis is low (12). The gonadotropes expressing FS may serve as autocrine regulators of FSH synthesis and secretion.
Recent studies by Kitaoka et al. (26) implicated GH cells as paracrine mediators of activin's action. Activin does not stimulate FSH release if the populations are plated too densely (28). When these authors added somatostatin to the media of the densely plated populations, the stimulatory effects of activin were recovered. Perhaps somatostatin inhibited FS release by GH cells, thereby freeing activin to stimulate FSH release.
To summarize, the overall objectives in this study were to localize follistatin mRNA in metestrous rats to learn if it could be expressed by pituitary cell types other than gonadotropes and fol-liculostellate cells. The findings show that expression of FS mRNA may be in somatotropes and mammotropes early in the cycle. Whereas this expression can serve to keep FSH secretion in check, after the high estrous secretory activity the previous day, the role of FS may be broader than that of regulation of FSH release. It may help control activin levels so that other cell types affected by activin can secrete normally.
